Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amgen acquires Avidia for $290mm plus $90mm earn-out

Executive Summary

Amgen has agreed to acquire the 96% of Avidia (developing therapeutics for inflammation, autoimmune diseases, cancer, and neurological conditions) that it does not already own for $290mm up front, plus two potential earn-outs--based on the development of certain compounds--that could total up to $90mm. Avidia, a Maxygen spin-off, will now be a wholly owned subsidiary of Amgen.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Full Acquisition
    • Acquisition of Private Biotech
    • Includes Contract
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register